VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
AGA111
Phase 3
Small molecule
A
Angitia Biopharmaceuticals
1
Indications
2
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Degenerative Disc Disease
Terminated
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Degenerative Disc Disease
Phase 3
Terminated
Clinical
Trials by Indication
[1]
Degenerative Disc Disease
2 trials
A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
Completed
·
A
Angitia Biopharmaceuticals
·
Phase 1/2
·
NCT05574543
·
60 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion
Terminated
·
A
Angitia Biopharmaceuticals
·
Phase 3
·
NCT06115512
·
412 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for AGA111. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
AGA111 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for AGA111. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Angitia Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
A
Angitia Biopharmaceuticals
Related News